EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Novel Therapeutics for Hepatocellular Carcinoma

Mohamed I Elsaid, Ashish Manne

Clinics in Liver Disease · 2025

DOI: 10.1016/j.cld.2025.06.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinics in Liver Disease, 2025. Verfasst von Mohamed I Elsaid und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics and Population Health, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genentech, AstraZeneca United States.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances have transformed the therapeutic landscape for advanced hepatocellular carcinoma (HCC). Immunotherapy combinations, such as atezolizumab-bevacizumab, ipilimumab-nivolumab, and STRIDE, have raised survival expectations, while novel checkpoints (LAG-3, TIGIT, TIM-3) and targeted therapies addressing FGFR4 and β-catenin are entering late-phase trials. Additionally, metabolic and stress-pathway inhibitors targeting ferroptosis, GLS1, NRF2, and YAP-TAZ show promising synergy with existing treatments. Precision oncology innovations, including liquid biopsy and AI-driven imaging, further enhance patient-tailored approaches. Addressing equity and global implementation barriers will ensure these advances benefit all patients, marking a decisive shift toward personalized and equitable HCC care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmunotherapyHumansMolecular Targeted TherapyImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

FGFR4 inhibitionFerroptosis inductionImmunotherapyLiquid biopsyNext-generation checkpoint inhibitorsPrecision oncologyβ-catenin modulation

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Biostatistics and Population Health, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA; Division of Medical Oncology, Department of Internal Medicine, Co…
  • Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.

Förderung

  • NCI NIH HHS
  • Genentech
  • AstraZeneca United States
  • NIH National Cancer Institute

Zitieren

APA

Elsaid, M. I., & Manne, A. (2025). Novel Therapeutics for Hepatocellular Carcinoma. Clinics in Liver Disease. https://doi.org/10.1016/j.cld.2025.06.009

Vancouver

Elsaid MI, Manne A. Novel Therapeutics for Hepatocellular Carcinoma. Clinics in Liver Disease. 2025. doi:10.1016/j.cld.2025.06.009

BibTeX
@article{Elsaid2025,
  author = {Elsaid, Mohamed I and Manne, Ashish},
  title = {Novel Therapeutics for Hepatocellular Carcinoma},
  journal = {Clinics in Liver Disease},
  year = {2025},
  doi = {10.1016/j.cld.2025.06.009}
}
Kostenlos starten →